Read on Twitter
Is Autologous HCT in Relapsed DLBCL Patients Achieving Only a PET+ PR Appropriate in the CAR-T cell Era? Question examined by @CIBMTR @niravshahmd @timfenske
#bmtsm #lymsm (1/6) https://pubmed.ncbi.nlm.nih.gov/33120429/
#bmtsm #lymsm (1/6) https://pubmed.ncbi.nlm.nih.gov/33120429/
249 PET+ DLBCL patients in PR, including 182 patients with early R-CHOP failure within 1-year
5-year adjusted PFS regardless of timing of R-CHOP failure ~40%........ (2/6)
5-year adjusted PFS regardless of timing of R-CHOP failure ~40%........ (2/6)
Recent years autoHCT numbers declining in USA, potentially driven by application of CAR-T in patients achieving PR only... (3/6)
Open question: Will application of CAR-T in this setting be superior to consolidative autoHCT? Worth examining but remains unknown...........(4/6)
Argument favoring autoHCT here (1) it potentially cures about 40-45% (2) low cost (3) can apply CAR-T in auto failures (4) not sure if reverse sequence will work......(5/6)
Limitations: 1. Registry analysis; 2. No central PET review; 3. Limited data on residual bulk at HCT (see manuscript Table 1); 4. Applies to only chemosensitive patients 5. This DOES NOT pertain to question being asked in ZUMA-7 etc.... (6/6)
